The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
20-May-25
Pending
Undisclosed
Target:
EYSA
Acquiror:
Tikehau Capital
Advising Tikehau Capital, global mid-market fund headquartered in France, in the acquisition of EYSA, a leading provider of smart mobility solutions, focusing on both urban and interurban mobility services for municipalities, transport authorities and infrastructure owners
17-Mar-25
Pending
$535 million
Target:
Notified
Acquiror:
Equiniti Group (a Siris Capital Group portfolio company)
Advising Equiniti Group, a Siris Capital Group portfolio company, on the acquisition of the Notified, a wholly owned subsidiary of West Technology Group., an Apollo Global Management portfolio company
13-Feb-25
$890 million
Target:
Renewi plc
Acquiror:
Consortium controlled by Macquarie Asset Management and BCI
Advising Renewi plc, a leading European waste-to-product company, on its £707 million recommended cash offer for its entire issued share capital from a consortium controlled by Macquarie Asset Management and British Columbia Infrastructure Management Corporation (BCI)
24-Dec-24
Undisclosed
Target:
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Acquiror:
Neuraxpharm Group
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
17-Dec-24
$962 million
Target:
Renewable assets in Chile involving hybrid solar power generation and storage
Acquiror:
Contour Global
Advised ContourGlobal (KKR) in the acquisition of 3 independent solar (Quillagua I & II, and Victor Jara) and BESS projects from Grenergy
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
04-Oct-24
Pending
Undisclosed
Target:
Radio Frequency Components Business of Renesas Electronics Corporation
Acquiror:
CG Power and Industrial Solutions
Exclusive advisor to Renesas, a global provider of microcontrollers, combining expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions
09-Sep-24
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
Henkel Corporation
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
30-May-24
Pending
Undisclosed
Target:
Renewi plc’s UK Municipal Business
Acquiror:
Biffa Limited
Advising Renewi plc, a leading European waste-to-product company, on the divestiture of its UK Municipal operations to Biffa Limited, a leading UK-wide integrated waste management business
13-Dec-23
Pending
Undisclosed
Target:
Vopak Moda Houston
Acquiror:
Exolum
Advising Exolum on its acquisition of 50% interest in Vopak Moda Houston, a leading ammonia and NGL storage & export terminal, from Moda Midstream (Encap Flatrock-Backed)
26-Oct-23
~$755 million
Target:
Innergex France
Acquiror:
Crédit Agricole Assurances
Advised Crédit Agricole Assurances, France’s largest insurance Group, in relation to its long-term partnership agreement with Innergex Renewable Energy Inc. (TSX: INE) and the acquisition of a 30% minority stake in Innergex France, the French operating and development activities of Innergex Renewable Energy Inc, for an enterprise value of €715m (@ 100%)
18-Sep-23
Pending
Undisclosed
Target:
Central nervous system (CNS) portfolio from Sanofi
Acquiror:
Pharmanovia
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
21-Jul-23
Undisclosed
Target:
Synfonium / Qwant / Shadow
Acquiror:
Caisse des Dépôts et Consignations (CDC) / Banque des Territoires
Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
28-Dec-22
Pending
Undisclosed
Target:
Eisai Distribution Co., Ltd.
Acquiror:
Yasuda Logistics Corporation
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
23-Dec-22
Pending
Undisclosed
Target:
Exyte Management GmbH
Acquiror:
BDT Capital Partners LLC
Advising Stumpf Capital and Georg Stumpf on the sale of a minority interest in its wholly-owned company, Exyte, a global leader in the design, engineering and delivery of high-tech facilities, to funds affiliated with BDT Capital Partners
16-Dec-22
Pending
$617 million
Target:
Asterion Energies
Acquiror:
Repsol
Advising Asterion Industrial Partners, a leading independent investment management firm, on the sale of their portfolio company Asterion Energies, a leading Pan-European renewable energy platform with over 7.7 GW of Solar PV and Wind assets in Spain, Italy and France
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
13-Sep-22
Undisclosed
Target:
InterGen N.V.’s UK business
Acquiror:
Bortela Capital s.r.o
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
02-Sep-22
Pending
$205 million
Target:
brsk
Acquiror:
Ares Management
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager